Prevention of influenza, especially in people at high risk of influenza complications. The use of the vaccine should be in accordance with official recommendations.
Composition:
1 dose (0.5 ml) contains a split, inactivated influenza virus containing antigens corresponding to the following strains: A (H1N1) - 15 μg HA, A (H3N2) - 15 μg HA and B - 15 μg HA (HA - haemagglutinin). The composition of the vaccine is updated annually depending on epidemiological data, as recommended by the WHO and the EU.
Action:
Inactivated influenza vaccine. The immunity is achieved within 2-3 weeks. The vaccination resistance to homologous strains to those contained in the vaccine or related strains varies, but usually lasts from 6 to 12 months.
Contraindications:
Hypersensitivity to the preparation ingredients, impurities, eggs and chicken protein. The vaccine in a single dose contains no more than 0.05 μg of ovalbumin. The following impurities may be present in the vaccine: formaldehyde, Gentamicin sulphate and sodium deoxycholate. Vaccination should be postponed in patients with a fever or acute illness.
Precautions:
The vaccine should under no circumstances be administered intravascularly. In patients with immune disorders, the immune response may be insufficient.
Pregnancy and lactation:
The use of the vaccine may be considered from the second trimester of pregnancy. In pregnant women who are at risk of influenza complications, it is recommended to administer the vaccine regardless of the stage of pregnancy. The vaccine can be used during breastfeeding.
Side effects:
Common (≥1 / 100, <1/10): local reactions - redness, swelling, petechiae, pain and induration at the injection site and general reactions - headache, increased sweating, muscle and joint pain, fever, malaise, chills, fatigue. In addition, transient thrombocytopenia, transient lymphadenopathy may occur; allergic reactions in rare cases leading to anaphylactic shock or angioneurotic edema, neuralgia, paraesthesia, febrile convulsions, encephalomyelitis, neuritis, Guillain-Barré syndrome, vasculitis, transient renal dysfunction, pruritus, urticaria, nonspecific rash .
Dosage:
Intramuscularly or deeply subcutaneously. Adults and children over 36 months: 0.5 ml (children under 9 years of age who have not been vaccinated before, the second dose should be given at least 4 weeks after the first dose); children after finishing 6 months up to 3 years of age: clinical data are limited, 0.25 ml or 0.5 ml doses are used.
(C)
